Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) witnessed a significant surge in its stock price on January 15, 2026, following the release of promising data from cohort...
TScan Therapeutics has announced encouraging results from its ALLOHA Phase 1 clinical trial, focusing on the treatment of hematological malignancies. The latest data indicates...